SCHEMBL4315419

SCHEMBL4315419

COc1c(OCCN2CCCC2=O)ccc(C=Cc2n[nH]c3ccccc23)c1[N+](=O)[O-]

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.42
KMT2A Q03164 5/20 0.42
MAPK1 P28482 1/20 0.37
KIT P10721 3/20 0.36
MAPT P10636 4/20 0.36
LMNA P02545 4/20 0.36
SMN1; SMN2 Q16637 4/20 0.36
ALDH1A1 P00352 4/20 0.36
NPC1 O15118 3/20 0.36
RAB9A P51151 3/20 0.36
HTT P42858 2/20 0.36
GAA P10253 2/20 0.36
HPGD P15428 2/20 0.34
POLB P06746 1/20 0.34
BRD4 O60885 1/20 0.34
TUBB4A P04350 1/20 0.34
TUBB P07437 1/20 0.34
TUBA3C P0DPH7 1/20 0.34
TUBA1B P68363 1/20 0.34
TUBA4A P68366 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4315410 1.00 MEN1 (0.42) MEN1KMT2AMAPK1KITMAPT
SCHEMBL4315513 0.87 MEN1 (0.45) MEN1KMT2AMAPK1KITLMNA
SCHEMBL4315506 0.87 MEN1 (0.45) MEN1KMT2AMAPK1KITLMNA
SCHEMBL4315423 0.86 KMT2A (0.37) MEN1KMT2AKITMAPTLMNA
SCHEMBL4315412 0.86 KMT2A (0.37) MEN1KMT2AKITMAPTLMNA
SCHEMBL4308261 0.83 MAPT (0.41) MEN1KMT2AMAPTLMNASMN1; SMN2
SCHEMBL4308256 0.83 MAPT (0.41) MEN1KMT2AMAPTLMNASMN1; SMN2
SCHEMBL4321984 0.80 MAPT (0.41) MEN1KMT2AMAPTLMNASMN1; SMN2
SCHEMBL4321978 0.80 MAPT (0.41) MEN1KMT2AMAPTLMNASMN1; SMN2
SCHEMBL4320360 0.80 MEN1 (0.57) MEN1KMT2AKITMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7605272-B2 IGF-1R inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-10-20 US disclosed
US-20090054508-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-02-26 US disclosed
EP-1847532-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-10-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054508-A1 IGF-1R INHIBITOR IGF1R, IGFBP5, IGFBP1 MEN1 1830/4885KMT2A 1924/4885MAPK1 295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.